A New Superagonist of GnRH for Inhibition of Ovulation in Women

S J Nillius, Sven Johan Nillius, Jens A. Guðmundsson, J Gudmundsson, C Bergquist, Christer Bergquist
Upsala journal of medical sciences · 1984 · vol. 89(2) , pp. 147–150 · doi:10.3109/03009738409178474 · PMID:6235657 · W1965187574
article OA: diamond CC0
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-15 ⓘ

Nafarelin acetate inhibited ovulation in 20 women over 12 weeks without estrogen deficiency symptoms, indicating potential contraceptive use and therapeutic value for endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-15 · read from full text ⓘ

This 1984 study evaluated the efficacy of a new gonadotropin-releasing hormone (GnRH) superagonist in suppressing ovulation among women. The researchers administered the compound to participants and monitored hormonal levels and ovarian function to determine its ability to inhibit follicular development and prevent ovulation. The findings demonstrated that the superagonist effectively induced a hypogonadotropic state, thereby successfully blocking the ovulatory process through continuous receptor stimulation. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

This paper presents the initial results from a study that used a new superagonist of gonadotrophin-releasing hormone (GnRH), naferelin acetate, for the inhibition of ovulation. The superagonist was administered by nasal spray daily for 12 weeks to 20 women with regular menstrual periods. Radioimmunoactive estradiol and progesterone were assayed weekly, and there were regular check ups and daily recordings of basal body temperature. None of the subjects had a normal ovulatory menstrual cycle during 57 treatment months. During the 1st 8 weeks, 7 women had menstrual-like bleeding, 8 had oligomenorrhea, and 5 were amenorrheic. No pregnancies occurred during the study, nor were there any clinical symptoms or signs of estrogen deficiency. These preliminary findings suggest that nafarelin is a potent antifertility drug with potential use for contraception. The antireproductive properties of the agonist are also of interest for treatment of tumors, gynecologic disorders such as endometriosis and polycystic ovarian disease, and precocious puberty.
Full text 2,201 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Acknowledgements

The Editorial team would like to publicly acknowledge all reviewers that volunteered their time and experise in the evaluation of manuscripts in 2025. The input of these individuals is crucial in maintaining the excellence of the journal.

Keywords

Upsala Journal of Medical Sciences | Online ISSN 2000-1967 | Print ISSN 0300-9734 Editors: Peter Hansell & Gerhard Wikström Published by the Upsala Medical Society under the terms of a Creative Commons CC-BY 4.0 license. Contact | Privacy Policy| @UpsJMedSci

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Contraceptives, Oral Contraceptives, Oral, Synthetic Gonadotropin-Releasing Hormone Ovulation Pituitary Hormone-Releasing Hormones Administration, Intranasal Adult Contraceptives, Oral Contraceptives, Oral, Synthetic Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Menstruation Menstruation Nafarelin Ovulation Pituitary Hormone-Releasing Hormones

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (5)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:09:55.985569+00:00
License: CC0 · commercial use OK